AzTrials
AzTrials

CholestasisNCT05582447

Osmotic Fragility in Red Blood Cells of Pediatric Patients With Cholestatic Liver Disease

An observational study of Cholestasis and Red Cell Membrane and Enzyme Abnormalities, run by Children's Hospital Medical Center, Cincinnati at 1 site in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Objective: The investigators propose to perform ektacytometry on 20 pediatric patients over age one with cholestatic liver diseases and a direct bilirubin level of greater than 2 gm/dl. Read more about this study

Who is it for?
Ages 1 year and olderHealthy volunteers can take part
What is being tested?
ektacytometry of red blood cells
How many people
40 participants
Where
1 siteUnited States
Study dates
17 Apr 2018to 31 Dec 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: Participants will be recruited from Cincinnati Children's Hospital hepatology and gastroenterology clinics. Pediatric patients over age one without cholestatic liver disease and pediatric patients over the age of one with cholestatic liver diseases and a direct bilirubin level of greater than 2 gm/dl.

Who may be able to join

  • Disease Cohort
  • Age greater than one year old
  • Direct bilirubin level of >2 mg/dl.
  • No known congenital red cell membrane defect
  • Controls
  • Age matched to disease cohort
  • No evidence for cholestatic liver disease
  • No known congenital red cell membrane defect

Who cannot join

  • Disease Cohort
  • Parental refusal
  • Age <1 year old.
  • Known congenital red cell membrane defect
  • Controls
  • Parental refusal
Show all 9Show fewer
  • Age <1 year old.
  • Known congenital red cell membrane defect
  • Cholestatic liver disease

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229

Other trials in United States

About this study

Official title: Pilot Study- Osmotic Fragility in Red Blood Cells of Pediatric Patients With Cholestatic Liver Disease

Objective:

The investigators propose to perform ektacytometry on 20 pediatric patients over age one with cholestatic liver diseases and a direct bilirubin level of greater than 2 gm/dl. The most common diagnoses will be extrahepatic biliary atresia, progressive familial intrahepatic cholestasis, Alagille syndrome, autoimmune hepatitis, primary sclerosing cholangitis, and parenteral nutrition-associated cholestasis. The investigators will correlate the osmotic fragility and deformability with direct bilirubin levels, serum cholesterol levels, serum bile acid levels, and vitamin E levels.

Read more

Design/Methods:

This pilot study will be a single center, prospective cross-sectional investigation of red blood cell ektacytometry in pediatric patients with extrahepatic cholestasis who are followed at Cincinnati Children's Hospital Medical Center. The study will include all participants with cholestasis regardless of the etiology in order to maximize the number of participants. While the population will be heterogeneous, the investigators will stratify participants according to diagnosis, recognizing that only a few participants may fall into each diagnostic category. Ektacytometry will be the method utilized to measure osmotic fragility and deformability of the RBC membrane. The ektacytometry of red cells from cholestatic patients will be compared to that of red cells obtained from contemporaneous age-matched controls recruited among patients without liver disease or red cell membrane defects undergoing blood sampling for evaluation of other entities including but not confined to functional abdominal pain.

Read the detailed description

Primary Aim:

The primary aim is to determine if ektacytometry of red blood cells is abnormal in a population of pediatric patients over age one with cholestasis.

Secondary Aims:

The secondary aim is to ascertain the extent at which abnormalities in bilirubin levels, bile acid levels, vitamin E levels or cholesterol levels in cholestatic patients are related to changes in red blood cell ektacytometry in this patient population.

BACKGROUND Cholestatic liver disease is an umbrella term for reduced bile flow from either extrahepatic obstruction of bile ducts or faulty hepatocyte bile secretion. Cholestasis is a well-recognized cause of dyslipidemia, and are closely associated with abnormal cholesterol and phospholipid metabolism (3). Cholesterol conversion to bile acids may be impaired, and apo-lipoprotein B binding to cholesterol may be impaired, resulting in the formation of lipoprotein X which contains apo-lipoprotein C (3). The end result of dyslipidemia in cholestatic patients is hypercholesterolemia and an increased membrane cholesterol to phospholipid ratio (3).

The lack of bile entering the digestive tract can lead to increased serum cholesterol, and abnormally high red cell membrane cholesterol: phospholipid ratios, resulting in altered red cell membrane structural integrity (4,5). To test for this phenomenon in patients with extrahepatic biliary atresia, 20 pediatric patients will be tested using ektacytometry to test the deformability and osmotic fragility of red blood cells.

Ektacytometry is a diagnostic tool used to measure the deformability of red blood cells on an osmotic gradient (6). More specifically it measures deformability due to shear stress, while the RBC are suspended in an osmotic medium (6,7). It can differentiate among several blood maladies such as hereditary spherocytosis, hereditary elliptocytosis, Southeast Asian ovalocytosis, and pyropoikilocytosis that are otherwise difficult to diagnose (8). It does this by analyzing rheological behavior under constant shear stress in vitro and using photometric analysis of deformability. This is then quantified and provides a specific ektacytometry curve (Figure 1).

The ektacytometry curve will have several unique features depending on the red blood cell being analyzed. The Omin portion of the curve represents the value of the osmolality in which 50 percent of the red blood cells lyse. The Elmax is the value of the elongation index that reaches its maximum near physiologic osmolality (300 mOsm/Kg). And lastly the Ohyp, which represents the declining portion of the curve and correlates to the initial intracellular viscosity of the cell sample.

To date, ektacytometry has not been employed systematically to characterize potential red cell abnormalities in cholestatic patients. In our analysis the ektacytometry profiles of cholestatic patients will be compared to those of historical non-cholestatic age-matched controls. The degree of fragility will be correlated with serum direct bilirubin levels, serum cholesterol levels, and vitamin E levels.

STUDY DESIGN This pilot study will be a single center, prospective cross-sectional investigation into the ektacytometry of red blood cells taken from 20 cholestatic pediatric patients followed at Cincinnati Children's Hospital. Patients are seen regularly for continued follow up in the hepatology clinic. Parents of all of these patients will be asked to participate in this investigation. The investigators will also contemporaneously analyze ektacytometry of 20 age-matched controls recruited from the general GI clinics with neither cholestatic liver disease nor know red cell membrane defects.

DURATION The study is anticipated to take approximately 6-12 months to complete. This time table includes 3-6 months to recruit patients and perform the assays and another 3-6 months to analyze the data and complete a manuscript.

Being tested
ektacytometry of red blood cells
Keywords
osmotic fragility
Medical subject headings
Cholestasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ektacytometry of red blood cellsOther

    Evaluate red blood cell membrane mechanical characteristics by osmotic gradient ektacytometry

Study groups in NCT05582447
Study groupRoleWhat they receive
Disease CohortAge greater than one year old Direct bilirubin level of >2 mg/dl. No known congenital red cell membrane defect
Receives: Other: ektacytometry of red blood cells
ControlAge matched to disease cohort No evidence for cholestatic liver disease No known congenital red cell membrane defect
Receives: Other: ektacytometry of red blood cells

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Red blood cell osmotic fragility

    Omin of osmotic fragility

    Measured: 1 year

  2. Red blood cell deformity

    EImax to measure deformity of red blood cells Ohyp measures index of red cell hydration

    Measured: 1 year

  3. Red blood cell hydration

    Ohyp to measure index of red cell hydration

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Oct 2022
  2. Study start17 Apr 2018
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Other
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05582447
Sponsor's protocol ID
2018-0310
Status last verified
Feb 2026
First submitted
10 Oct 2022
Last updated
6 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: No IPD will be available with researchers beyond those as part of the study team at Cincinnati Children's Hospital Medical Center

Publications

  • Kocoshis TS, Kalfa TA, Miethke AG, Balistreri WF, Seu KG, Slaughter CG, Singh R, Mullen M, Kocoshis SA. Red cell abnormalities characterized by ektacytometry in children with cholestasis. Pediatr Res. 2024 Mar;95(4):1035-1040. doi: 10.1038/s41390-023-02899-2. Epub 2023 Dec 1.

    PubMed 38040987

Questions about this trial

What is this clinical trial studying?

An observational study of Cholestasis and Red Cell Membrane and Enzyme Abnormalities, run by Children's Hospital Medical Center, Cincinnati at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 6 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Red blood cell osmotic fragility (time frame: 1 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05582447, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in